PremiumCompany AnnouncementsCSPC Pharmaceutical Group Reports Q1 2025 Earnings CSPC Pharmaceutical Group in Talks for Major Licensing Deals CSPC Pharmaceutical Group Reports Decline in Q1 2025 Results Amid Industry Challenges PremiumCompany AnnouncementsCSPC Pharmaceutical Group’s New Drug Approval Enhances Digestive Treatment Portfolio CSPC Pharmaceutical’s Heart Failure Drug Gains U.S. Clinical Trial Approval CSPC Pharmaceutical’s JMT202 Receives U.S. FDA Clinical Trial Approval PremiumCompany AnnouncementsCSPC Pharmaceutical’s JMT203 Receives U.S. FDA Approval for Clinical Trials CSPC Pharmaceutical Gains Approval for Diabetes Drug Trials CSPC Pharmaceutical’s Oseltamivir Suspension Gains Approval in China